Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer

{"sci_version": "1.0", "schema": "https://corpus.bntrg.co.uk/sci/1.0/sci.schema.json", "id": "pmid:34248362", "kind": "science-record", "revision": 2, "content_hash": "sha256:f04a690d864015a4cd68c0e1b1bbc1f5c6f7a8de1e0a470c48c203852401c1ec", "created_at": "2026-11-01T10:25:48Z", "updated_at": "2026-11-01T14:01:31Z", "generator": {"name": "corpus-assay-engine", "converter": "sep_to_sci_v1", "source_package_schema": "urn:bntrg:sep:1.0.0"}, "paper": {"state": "partial", "title": "Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer", "doi": "10.1177/11795549211004489", "pmid": "34248362", "authors": null, "journal": "Clinical Medicine Insights. Oncology", "year": 2021, "abstract": null, "claims": [{"id": "claim-1", "statement": "the median overall survival of patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitor monotherapy", "kind": "quantitative", "state": "complete", "target": {"value": 12.4, "unit": "months", "tolerance": null, "source": "chars 8249-8744 of source sha256 c896e7fb83e4c1316132a9d317c903bc2ede63bdfd73689c1cc743353dd42eaf"}, "evidence": [{"asset": "source:pmid:34248362", "locator": "chars 8249-8744 of source sha256 c896e7fb83e4c1316132a9d317c903bc2ede63bdfd73689c1cc743353dd42eaf", "quote": "In the NSCLC cohort, the objective response rate (ORR) was 32.0% (95% CI, 25.6%-39.0%). Ten (5.0%) patients had complete response, and 54 (27.0%) had partial response (Table 3). Median PFS was 3.8 months (4.7 months for first-line therapy and 3.7 months for subsequent-line therapy). The estimated rate of PFS was 38.8% at 6 months, 27.8% at 12 months, and 18.2% at 24 months (Figure 1). Median OS was 12.4 months (15.6 months for first-line therapy and 11.5 months for subsequent-line therapy)."}]}], "gaps": ["abstract", "authors"]}, "experiment": {"state": "partial", "objective": "the median overall survival of patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitor monotherapy", "steps": [{"id": "read_published_estimate", "order": 1, "name": "Read the published estimate and its interval from the source", "kind": "other", "state": "complete", "blocked_on": null, "description": "The number a replication must land on, and the sentence it came from.", "duration_hours": null, "parameters": {}, "inputs": ["source:pmid:34248362"], "outputs": ["the published estimate, its unit and its interval"], "instruments": [], "reagents": []}, {"id": "obtain_source_data", "order": 2, "name": "Obtain the source data behind the published result", "kind": "data-preparation", "state": "blocked", "blocked_on": "data:accession_absent", "description": "The published result cannot be recomputed without the data the paper analysed.", "duration_hours": null, "parameters": {}, "inputs": [], "outputs": ["the source data with its provenance"], "instruments": [], "reagents": []}, {"id": "run_analysis", "order": 3, "name": "Run the analysis programme", "kind": "analysis", "state": "blocked", "blocked_on": "method:epidemiological_modelling_incidence_rate", "description": "Re-run the paper's analysis on the source data and produce the registered result.", "duration_hours": null, "parameters": {}, "inputs": ["materials:the source data behind the published result in pmid:34248362"], "outputs": ["the registered result"], "instruments": [], "reagents": []}, {"id": "provide_capability_bench_workcell", "order": 4, "name": "Provide General bench workcell (liquid transfer, plate handling, incubation)", "kind": "computational", "state": "blocked", "blocked_on": "instrument not yet purchased", "description": "Make this capability available to the experiment: amplicon_seq, animal_model, apoptosis_assay, cell_culture, cell_imaging, chip_seq, clinical_cohort, clinical_trial, elisa, flow_cytometry, ihc, image_quantification, mass_spectrometry, methylation_array, microarray, qpcr, rna_seq, transfection, western_blot", "duration_hours": null, "parameters": {}, "inputs": [], "outputs": [], "instruments": [], "reagents": []}], "materials": ["the source data behind the published result in pmid:34248362", "the analysis programme that recomputes the published estimate"], "instruments": [], "reagents": [], "conditions": {}, "gaps": ["step:obtain_source_data blocked on data:accession_absent", "step:provide_capability_bench_workcell blocked on instrument not yet purchased", "step:run_analysis blocked on method:epidemiological_modelling_incidence_rate"]}, "data": {"state": "partial", "assets": [{"id": "source:pmid:34248362", "role": "manuscript", "format": "xml", "media_type": "application/xml", "uri": "https://doi.org/10.1177/11795549211004489", "sha256": "sha256:c896e7fb83e4c1316132a9d317c903bc2ede63bdfd73689c1cc743353dd42eaf", "bytes": null, "access": "open", "state": "resolved", "reader": null, "reader_status": "reader_required", "identifier": "10.1177/11795549211004489", "version": null, "note": "Source read by the package builder: full_text.", "structure": {"access_state": "full_text"}}, {"id": "materials:the source data behind the published result in pmid:34248362", "role": "raw", "format": "unknown", "media_type": "application/octet-stream", "uri": null, "sha256": null, "bytes": null, "access": "unknown", "state": "unavailable", "reader": null, "reader_status": "unknown", "identifier": null, "version": null, "note": "the source data behind the published result in pmid:34248362", "structure": {"material_kind": "dataset", "access_state": "not_identified"}}, {"id": "materials:the analysis programme that recomputes the published estimate", "role": "code", "format": "unknown", "media_type": "application/octet-stream", "uri": null, "sha256": null, "bytes": null, "access": "unknown", "state": "unavailable", "reader": null, "reader_status": "unknown", "identifier": null, "version": null, "note": "the analysis programme that recomputes the published estimate", "structure": {"material_kind": "code", "access_state": "absent"}}, {"id": "asset:table:pmid:34248362:1", "role": "table", "format": "jats-table", "media_type": "application/vnd.jats.table+json", "uri": null, "sha256": "sha256:a81e900d9ce470ab9201aae2a1252684f8c3321f23a5aa0c9359c1e71a323d05", "bytes": 218, "access": "open", "state": "verified", "reader": "read_table", "reader_status": "available", "identifier": "section[7]/table-wrap[1]#table1-11795549211004489", "version": null, "note": "Patient demographic and disease characteristics.", "structure": {"pmcid": "PMC8237437", "section_index": 7, "section_title": "Patient and disease characteristics", "row_count": 0, "column_count": 0}, "table": {"label": "Table 1.", "caption": "Patient demographic and disease characteristics.", "rows": [], "row_count": 0, "column_count": 0, "numeric_cells": 0, "header_rows": 0, "locator": "section[7]/table-wrap[1]#table1-11795549211004489"}}, {"id": "asset:table:pmid:34248362:2", "role": "table", "format": "jats-table", "media_type": "application/vnd.jats.table+json", "uri": null, "sha256": "sha256:a08d00d10f84231c0a390de07a94e02687669796c580c467d38fcf7af9b4c189", "bytes": 196, "access": "open", "state": "verified", "reader": "read_table", "reader_status": "available", "identifier": "section[7]/table-wrap[2]#table2-11795549211004489", "version": null, "note": "Molecular characteristics.", "structure": {"pmcid": "PMC8237437", "section_index": 7, "section_title": "Patient and disease characteristics", "row_count": 0, "column_count": 0}, "table": {"label": "Table 2.", "caption": "Molecular characteristics.", "rows": [], "row_count": 0, "column_count": 0, "numeric_cells": 0, "header_rows": 0, "locator": "section[7]/table-wrap[2]#table2-11795549211004489"}}, {"id": "asset:table:pmid:34248362:3", "role": "table", "format": "jats-table", "media_type": "application/vnd.jats.table+json", "uri": null, "sha256": "sha256:a31e0ac4c36ba57def663b55c252421f961f303b489cb53b7a9bde336ead2dd6", "bytes": 190, "access": "open", "state": "verified", "reader": "read_table", "reader_status": "available", "identifier": "section[8]/table-wrap[1]#table3-11795549211004489", "version": null, "note": "Summary of response.", "structure": {"pmcid": "PMC8237437", "section_index": 8, "section_title": "Treatment outcomes", "row_count": 0, "column_count": 0}, "table": {"label": "Table 3.", "caption": "Summary of response.", "rows": [], "row_count": 0, "column_count": 0, "numeric_cells": 0, "header_rows": 0, "locator": "section[8]/table-wrap[1]#table3-11795549211004489"}}, {"id": "asset:table:pmid:34248362:4", "role": "table", "format": "jats-table", "media_type": "application/vnd.jats.table+json", "uri": null, "sha256": "sha256:93b85d2069a96acb9b9f022ffd622ac001b6ede501a229c64a7529b7a3c15b89", "bytes": 200, "access": "open", "state": "verified", "reader": "read_table", "reader_status": "available", "identifier": "section[9]/table-wrap[1]#table4-11795549211004489", "version": null, "note": "Immune-related adverse events.", "structure": {"pmcid": "PMC8237437", "section_index": 9, "section_title": "Immune-related adverse events", "row_count": 0, "column_count": 0}, "table": {"label": "Table 4.", "caption": "Immune-related adverse events.", "rows": [], "row_count": 0, "column_count": 0, "numeric_cells": 0, "header_rows": 0, "locator": "section[9]/table-wrap[1]#table4-11795549211004489"}}, {"id": "asset:table:pmid:34248362:5", "role": "table", "format": "jats-table", "media_type": "application/vnd.jats.table+json", "uri": null, "sha256": "sha256:1a58c8b1bd01d7a6b33f6bae8f3b365e697c9e548de7303992a039f780b37f44", "bytes": 301, "access": "open", "state": "verified", "reader": "read_table", "reader_status": "available", "identifier": "section[12]/table-wrap[1]#table5-11795549211004489", "version": null, "note": "Cox proportional hazard regression analysis of the effect of various parameters on progression-free survival and overall survival.", "structure": {"pmcid": "PMC8237437", "section_index": 12, "section_title": "Predictive factors associated with survival outcomes in NSCLC", "row_count": 0, "column_count": 0}, "table": {"label": "Table 5.", "caption": "Cox proportional hazard regression analysis of the effect of various parameters on progression-free survival and overall survival.", "rows": [], "row_count": 0, "column_count": 0, "numeric_cells": 0, "header_rows": 0, "locator": "section[12]/table-wrap[1]#table5-11795549211004489"}}], "gaps": ["asset:materials:the analysis programme that recomputes the published estimate not verified", "asset:materials:the source data behind the published result in pmid:34248362 not verified", "asset:source:pmid:34248362 not verified"]}, "analysis": {"state": "partial", "methods": [{"id": "method-1", "family": "survival_analysis", "specific": "cox regression", "label": "Survival analysis", "dsl_operations": ["cox_ph"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["time_to_event_with_censoring"], "evidence": {"score": 0.7, "band": "medium", "quote": "Medical records of patients with advanced lung cancer who started ICI monotherapy were reviewed for data collection. Treatment outcomes included objective response rate, progression-free survival (PFS), and overall survival (OS). Immune-related adverse events (irAEs) were assessed. Multiple Cox regression models were fit to investigate the predictive factors for survival outcomes."}}], "targets": [{"id": "target-1", "claim_id": "claim-1", "operation": null, "expected_value": 12.4, "unit": "months", "tolerance": null, "state": "complete"}], "gaps": []}, "capability": {"state": "partial", "requirements": [{"capability_id": "capability:computational_analysis", "label": "Computational analysis platform", "assay_families": ["differential_expression", "gwas", "machine_learning", "meta_analysis", "molecular_docking", "network_analysis", "pca", "statistical_regression", "survival_analysis"], "availability_state": "owned", "tier_unlocked": "R1", "candidate": "Automated Assays Laravel application and simulated adapters"}, {"capability_id": "capability:bench_workcell", "label": "General bench workcell (liquid transfer, plate handling, incubation)", "assay_families": ["amplicon_seq", "animal_model", "apoptosis_assay", "cell_culture", "cell_imaging", "chip_seq", "clinical_cohort", "clinical_trial", "elisa", "flow_cytometry", "ihc", "image_quantification", "mass_spectrometry", "methylation_array", "microarray", "qpcr", "rna_seq", "transfection", "western_blot"], "availability_state": "purchasable", "tier_unlocked": "R3", "candidate": "Supplier-neutral 96/384-well liquid handler"}], "gaps": ["capability:capability:bench_workcell purchasable"]}, "readiness": {"state": "blocked", "tier": "R4", "blocking_axis": "data", "blocked_on": "data:accession_absent", "axes": {"method": {"axis": "method", "tier": "R1", "blocker": null, "detail": {"outcome": "determined", "family": "survival_analysis", "specific_method": "cox_proportional_hazards", "required_operations": ["cox_ph"], "basis": "Every DSL operation this method needs already exists."}}, "capability": {"axis": "capability", "tier": "R1", "blocker": null, "detail": {"families": [], "applies": false, "basis": "This paper needs no bench capability: it computes on data it already has."}}, "data": {"axis": "data", "tier": "R4", "blocker": "data:accession_absent", "detail": {"applies": true, "reachable": false, "basis": "The record names no repository accession and no data-availability statement, so the source data has to be requested from the authors."}}}, "can_run": {"dsl_operations": ["cox_ph"], "assets": ["source:pmid:34248362", "asset:table:pmid:34248362:1", "asset:table:pmid:34248362:2", "asset:table:pmid:34248362:3", "asset:table:pmid:34248362:4", "asset:table:pmid:34248362:5"], "steps": ["read_published_estimate"]}, "must_build": {"dsl_operations": [], "converters": [], "readers": ["unknown", "xml"], "capabilities": ["capability:bench_workcell"], "data_gaps": ["source:pmid:34248362", "materials:the source data behind the published result in pmid:34248362", "materials:the analysis programme that recomputes the published estimate"]}, "gaps": ["data:accession_absent"]}, "review": {"state": "partial", "machine_critique": {"status": "passed", "providers": [{"provider": "minimax-m3-1-flash", "model": "MiniMax-M3.1-Flash", "prompt_version": "peer-review-reading-v1", "prompt_hash": "c0c64e571bae1f6795c3dfc12736e0b860eaf4d65f2936e1eaacdd2996130d39", "source_hash": "c896e7fb83e4c1316132a9d317c903bc2ede63bdfd73689c1cc743353dd42eaf", "raw_response_sha256": "sha256:5d1df3b52cf6e134e37c0ea75f23a8e27e1a5baea24fd28bd42dc18ac41f8bad", "raw_response_chars": 1033}, {"provider": "minimax-m3", "model": "MiniMax-M3", "prompt_version": "peer-review-reading-v1", "prompt_hash": "10a417df5f5271d628c2f7d81a8b0a0bcd778bd280883b4442fcc49e178c76a6", "source_hash": "c896e7fb83e4c1316132a9d317c903bc2ede63bdfd73689c1cc743353dd42eaf", "raw_response_sha256": "sha256:d601d2c22d2bf15801002cea305131c35c314707f2608986dd75556f95826e68", "raw_response_chars": 1884}], "target_providers": [{"provider": "minimax-m3-1-flash", "model": "MiniMax-M3.1-Flash", "prompt_version": "replication-target-v2", "prompt_hash": "0db7475e2238931f85fbd25027fcf973ae65bae9e8fb151448027420a0034c89", "source_hash": "c896e7fb83e4c1316132a9d317c903bc2ede63bdfd73689c1cc743353dd42eaf", "raw_response": "{\"parent_value\":12.4,\"unit\":\"months\",\"evidence\":\"In the NSCLC cohort, the objective response rate (ORR) was 32.0% (95% CI, 25.6%-39.0%). Ten (5.0%) patients had complete response, and 54 (27.0%) had partial response (Table 3). Median PFS was 3.8 months (4.7 months for first-line therapy and 3.7 months for subsequent-line therapy). The estimated rate of PFS was 38.8% at 6 months, 27.8% at 12 months, and 18.2% at 24 months (Figure 1). Median OS was 12.4 months (15.6 months for first-line therapy and 11.5 months for subsequent-line therapy).\",\"target_result\":\"Median overall survival was 12.4 months.\",\"number_stated\":true}", "reading": {"parent_value": 12.4, "unit": "months", "evidence": "In the NSCLC cohort, the objective response rate (ORR) was 32.0% (95% CI, 25.6%-39.0%). Ten (5.0%) patients had complete response, and 54 (27.0%) had partial response (Table 3). Median PFS was 3.8 months (4.7 months for first-line therapy and 3.7 months for subsequent-line therapy). The estimated rate of PFS was 38.8% at 6 months, 27.8% at 12 months, and 18.2% at 24 months (Figure 1). Median OS was 12.4 months (15.6 months for first-line therapy and 11.5 months for subsequent-line therapy).", "target_result": "Median overall survival was 12.4 months.", "number_stated": true, "source_locator": "chars 8249-8744 of source sha256 c896e7fb83e4c1316132a9d317c903bc2ede63bdfd73689c1cc743353dd42eaf"}, "recorded_at": "2026-10-31T14:36:01.691365+00:00"}, {"provider": "minimax-m3", "model": "MiniMax-M3", "prompt_version": "replication-target-v2", "prompt_hash": "ec191c6d678aa915fdb9ce9cfc92245db97428fca1fa3bf9c9fd69b30a933564", "source_hash": "c896e7fb83e4c1316132a9d317c903bc2ede63bdfd73689c1cc743353dd42eaf", "raw_response": "{\"parent_value\":12.4,\"unit\":\"months\",\"evidence\":\"In NSCLC, median PFS was 3.8 months (4.7 months for first line and 3.7 months for subsequent line). Median OS was 12.4 months (15.6 months for first line therapy and 11.5 months for subsequent line).\",\"target_result\":\"Median overall survival was 12.4 months.\",\"number_stated\":true}", "reading": {"parent_value": 12.4, "unit": "months", "evidence": "In NSCLC, median PFS was 3.8 months (4.7 months for first line and 3.7 months for subsequent line). Median OS was 12.4 months (15.6 months for first line therapy and 11.5 months for subsequent line).", "target_result": "Median overall survival was 12.4 months.", "number_stated": true, "source_locator": "chars 1044-1243 of source sha256 c896e7fb83e4c1316132a9d317c903bc2ede63bdfd73689c1cc743353dd42eaf"}, "recorded_at": "2026-10-31T14:36:10.722441+00:00"}], "agreement": true, "disagreements": {"target_result": {"minimax-m3-1-flash": "Median overall survival was 12.4 months in patients with advanced NSCLC treated with immune checkpoint inhibitor monotherapy.", "minimax-m3": "Median overall survival was 12.4 months in the advanced NSCLC cohort treated with immune checkpoint inhibitor monotherapy.", "decisive": false}, "analysis_methods": {"minimax-m3-1-flash": ["Kaplan-Meier estimation of overall survival", "Multiple Cox regression analysis"], "minimax-m3": ["Retrospective medical-record review of a consecutive advanced lung cancer cohort", "Kaplan-Meier estimation of overall survival and progression-free survival", "Multiple Cox regression modeling of prognostic factors for survival outcomes"], "decisive": false}, "source_claims": {"minimax-m3-1-flash": ["In the NSCLC cohort, median PFS was 3.8 months (4.7 months for first-line therapy and 3.7 months for subsequent-line therapy).", "Median OS was 12.4 months (15.6 months for first-line therapy and 11.5 months for subsequent-line therapy).", "Overall survival (OS) was defined as time from the start of ICI treatment to death due to any cause.", "Kaplan-Meier curves were calculated for OS and PFS."], "minimax-m3": ["The study retrospectively reviewed medical records of 220 patients with advanced lung cancer who received single-agent atezolizumab, nivolumab, or pembrolizumab.", "In the NSCLC cohort, median OS was 12.4 months.", "Median OS was 15.6 months for first-line therapy and 11.5 months for subsequent-line therapy.", "Kaplan-Meier curves were calculated for OS and PFS, and Cox regression was used to model prognostic factors."], "decisive": false}}, "agreement_basis": {"policy": "decisive_fields", "decisive_fields": ["number_stated", "parent_value", "unit", "work_type"], "advisory_fields": ["analysis_methods", "source_claims", "target_result"]}, "blinded": true}, "human_critique": {"status": "not_run", "reviewer": null, "signed_at": null, "conflict_checked": false, "commentary": null}, "stages": [{"key": "target_materials", "status": "pending", "reason": null, "evidence": null}, {"key": "independent_readings", "status": "passed", "reason": null, "evidence": {"provider_errors": []}}, {"key": "source_resolution", "status": "pending", "reason": null, "evidence": null}, {"key": "protocol_reconstruction", "status": "pending", "reason": null, "evidence": null}, {"key": "control_execution", "status": "pending", "reason": null, "evidence": null}, {"key": "control_comparison", "status": "pending", "reason": null, "evidence": null}, {"key": "publication", "status": "pending", "reason": null, "evidence": null}], "gaps": ["review.human_critique", "review.machine_critique.passed"]}, "execution": {"state": "absent", "status": "not_run", "mode": null, "runs": [], "gaps": ["execution.not_run"]}, "provenance": {"entities": [{"id": "package:7b08e8e16e2d1051f325081abca3a53fec0dff0838350ad3f04b8761f04e3821", "type": "sep_package", "label": "SEP v1 package for pmid:34248362"}], "activities": [{"id": "activity:conversion:pmid:34248362", "type": "conversion", "used": ["package:7b08e8e16e2d1051f325081abca3a53fec0dff0838350ad3f04b8761f04e3821"], "agent": "agent:corpus-assay-engine"}], "agents": [{"id": "agent:minimax-m3", "type": "model", "label": "minimax-m3"}, {"id": "agent:minimax-m3-1-flash", "type": "model", "label": "minimax-m3-1-flash"}, {"id": "agent:corpus-assay-engine", "type": "software", "label": "Corpus assay engine"}], "source_run_id": "run-20261023T122449232913", "dsl_catalogue_fingerprint": "343fb30756ba6ec3", "capability_table_fingerprint": "2cb3e42f047d2ecf", "snapshot_id": "ba34b49490d9bfaf"}, "lineage": {"parent_id": "pmid:34248362", "parent_hash": "sha256:4d38fd2f33287ea1d7f6070b05ce902811ad5ab84633a9d5d8bce674adafe941", "fork_of": null, "generation": 2}, "gaps": ["abstract", "asset:materials:the analysis programme that recomputes the published estimate not verified", "asset:materials:the source data behind the published result in pmid:34248362 not verified", "asset:source:pmid:34248362 not verified", "authors", "capability:capability:bench_workcell purchasable", "data:accession_absent", "execution.not_run", "review.human_critique", "review.machine_critique.passed", "step:obtain_source_data blocked on data:accession_absent", "step:provide_capability_bench_workcell blocked on instrument not yet purchased", "step:run_analysis blocked on method:epidemiological_modelling_incidence_rate"]}